IMMUNOHISTOCHEMICALLY EVALUATION OF CD20 EXPRESSION IN PATIENTS WITH MULTIPLE MYELOMA

• Published in: Mediterranean Journal of Hematology and Infectious Diseases
• Main Authors: Irfan Yavasoglu, Gokhan Sargin, Gurhan Kadikoylu, Firuzan Kacar Doger, Zahit Bolaman
• Format: Article
• Language: English
• Published: PAGEPress Publications 2014-08-01
• Subjects: multiple myeloma; CD20; immunohistochemistry; Durie-Salmon stage
• Online Access: https://mjhid.org/index.php/mjhid/article/view/1794

Objective: CD20 expression was reported in different rates in patients with multiple myeloma. The importance of this B-cell antigen is still unknown for plasma cells. We aimed to investigate CD20 expression of myeloma cells in bone marrow, also relationship between stage of disease, isotype and clinical features. Materials and Methods: Sixty-one patients who admitted to our hematology clinic with the diagnosis of multiple myeloma according to the criteria of "International Myeloma Working Group" were enrolled the study. Age, sex, Durie-Salmon stage, the history of autologous hematopoietic stem cell transplantation, the distribution pattern and positivity of CD20 for myeloma cells in bone marrow were evaluated. Mann-Whitney U and chi-square tests were performed as statistical analysis and p< 0.05 was accepted as statistically significant. Results: Thirty patients (48.9%) had positive score for CD20 and the distribution pattern were almost likely interstitial in 55.6%. There was no statistically significant difference between immunohistochemical positivity for CD20 of myeloma cells, immunoglobulin type, values and the stage of disease. Conclusion: The combination of immunohistochemical studies with flow cytometry could reveal more clearly for the importance of CD20 positivity in patients with multiple myeloma.